0.20Open0.20Pre Close0 Volume1.41K Open Interest47.00Strike Price0.00Turnover0.00%IV32.70%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier-1DDays to Expiry0.20Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma177.85Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Northern Oil & Gas Stock Discussion
• $Northern Oil & Gas (NOG.US)$ +6.1% (to join S&P SmallCap 600)
• $American Express (AXP.US)$ + 5.3% (Fourth-quarter results at American Express fell short of expectations but Wall Street was more interested in the company’s plans to return capital to shareholders)
• $Lockheed Martin (LMT.US)$ +0.6% (awarded $657 mln U.S. Army contract modification)
Gapping down
• $Intel (INTC.US)$ -10.5% (Intel reported its Q4 2022...
When asked about Northern Oil and Gas, Inc.
NOG $Northern Oil & Gas (NOG.US)$ , he said, "I’d rather see you in something that right now, works."
"I believe that it is a call option on natural gas," Cramer said, when asked about ...
• $Livent (LTHM.US)$ +22.58% (it posted better-than-expected quarterly earnings and raised its 2022 revenue forecast)
• $Super Micro Computer (SMCI.US)$ +11.01% (earnings reports)
• $Oatly Group AB (OTLY.US)$ +8.31% (earnings reports)
• $BlueLinx Holdings (BXC.US)$ +9.7% (increases share repurchase authorization to $100 mln; enters into $60 mln accelerated repurchase agreement)
• $Starbucks (SBUX.US)$ +7.18% (matched estimates wi...
• $Ascendis Pharma A/S (ASND.US)$: BofA Securities Upgrades to Buy from Neutral - PT $161 (from $148)
• $GoodRx (GDRX.US)$: Baird Upgrades to Outperform from Neutral - PT $17
• $W.W. Grainger (GWW.US)$: Atlantic Equities Upgrades to Overweight from Neutral - PT $580 (from $520)
• $Heartland Express (HTLD.US)$: Morgan Stanley Upgrades to Equalweight from Underweight - PT $16
• $The Mosaic (MOS.US)$: Goldman Sachs Upgrades to Buy from Neutral - PT $83
• $Northern Oil & Gas (NOG.US)$: Johnson ...
- $Luna Innovations (LUNA.US)$ +8.55% (acquires LIOS Sensing from NKT A/S' NKT Photonics for 20 million in cash; divested Luna Labs for $21 mln)
- $Clene (CLNN.US)$ +3.5% (Presents Updated Clinical Data from Phase 2 RESCUE-ALS and REPAIR trials and Preclinical ALS data at 2022 MDA Clinical & Scientific Conference)
- $AstraZeneca (AZN.US)$ +2.3% ( AstraZeneca and $Merck & Co (MRK.US)$ 's Lynparza (olaparib) has been approved in the ...
No comment yet